Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 3, 2014, Pages 289-297

  Mayer Hamblett, Nicole ^a,b,c   Rosenfeld, Margaret ^a,c   Gibson, Ronald L ^a,c   Ramsey, Bonnie W ^a,c   Kulasekara, Hemantha D ^b   Retsch Bogart, George Z ^d   Morgan, Wayne ^e   Wolter, Daniel J ^a   Pope, Christopher E ^a   Houston, Laura S ^a   Kulasekara, Bridget R ^b   Khan, Umer ^c   Burns, Jane L ^a,c   Miller, Samuel I ^a,b   Hoffman, Lucas R ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Exacerbation; Mucoid Pseudomonas aeruginosa; Pulmonary function; Risk factors

Indexed keywords

PROTEINASE; PYOVERDINE;

ARTICLE; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHILD; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TWITCHING MOTILITY; ADOLESCENT; DISEASE COURSE; EPIDEMIOLOGY; EXACERBATION; GENETICS; INFANT; ISOLATION AND PURIFICATION; LUNG FUNCTION; MICROBIOLOGY; MUCOID PSEUDOMONAS AERUGINOSA; MULTICENTER STUDY (TOPIC); PRESCHOOL CHILD; RISK FACTOR; STATISTICAL MODEL;

EPIDEMIOLOGY; EXACERBATION; MUCOID PSEUDOMONAS AERUGINOSA; PULMONARY FUNCTION; RISK FACTORS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; LOGISTIC MODELS; MALE; MULTICENTER STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PHENOTYPE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84907296644     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201404-0681OC     Document Type: Article

References (49)

1. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
2. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12: 158-161.
3. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19:10-15.
4. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-406.
5. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116:714-719.
6. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. Journal of Pediatrics 2007;151:134-139, 139 e1.
7. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, Green CG, Collins J, Farrell PM. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-287.
8. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
9. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
10. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-588.
11. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-689.
12. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Hoiby N, Molin S. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: An evolutionary perspective. Nat Rev Microbiol 2012;10: 841-851.
13. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011;24:29-70.
14. Haussler S, Tummler B, Weissbrodt H, Rohde M, Steinmetz I. Smallcolony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 1999;29:621-625.
15. Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun 1994;62:596-605.
16. Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI. Pseudomonas aeruginosa lasr mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 2009;8:66-70.
17. Hunter RC, Klepac-Ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am J Respir Cell Mol Biol 2012;47:738-745.
18. Tingpej P, Smith L, Rose B, Zhu H, Conibear T, Al Nassafi K, Manos J, Elkins M, Bye P, Willcox M, et al. Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis. J Clin Microbiol 2007;45: 1697-1704.
19. Manos J, Hu H, Rose BR, Wainwright CE, Zablotska IB, Cheney J, Turnbull L, Whitchurch CB, Grimwood K, Harmer C, et al. Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2013;32: 1583-1592.
20. Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, Bar-Meir M, Sullivan CL, McColley SA, Hauser AR. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004;42: 5229-5237.
21. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-623.
22. Mayer-Hamblett N, Ramsey BW, Kulasekara H, Wolter DJ, Houston L, Pope C, Kulasekara B, Armbruster C, Burns JL, Retsch-Bogart G, et al. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin Infect Dis (In press)
23. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials 2009;30:256-268.
24. Mayer-Hamblett N, Gibson RL, Rosenfeld M, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, Wolter DJ, Pope CE, Houston LS, Kulasekara BR, Foster JM, Khan U, Burns JL, Miller SI, Hoffman LR. Pseudomonas aeruginosa phenotypes distinguish initial, intermittent, and persistent stages of cf airway infection (abstract). Pediatr Pulmonol 2013;36(Suppl):303.
25. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29-34.
26. Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M. Clinical outcomes after initial Pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol (In press)
27. Diggle P, Heagerty P, Liang KY, Zeger S. Analysis of longitudinal data. Oxford, UK: Oxford University Press; 2002.
28. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006;103: 8487-8492.
29. Jeukens J, Boyle B, Kukavica-Ibrulj I, Ouellet MM, Aaron SD, Charette SJ, Fothergill JL, Tucker NP, Winstanley C, Levesque RC. Comparative genomics of isolates of a Pseudomonas aeruginosa epidemic strain associated with chronic lung infections of cystic fibrosis patients. PLoS ONE 2014;9:e87611.
30. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-808.
31. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
32. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
33. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166: 1550-1555.
34. Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, Diggle P. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: A longitudinal study. Thorax 2012;67:860-866.
35. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-574.
36. Staudinger BJ, Muller JF, Halldorsson S, Boles B, Angermeyer A, NguyenD,Rosen H, Baldursson O, GottfreethssonM, Guethmundsson GH, et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189:812-824.
37. Sanders DB, Li Z, Laxova A, Rock MJ, Levy H, Collins J, Ferec C, Farrell PM. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 2014;11:63-72.
38. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
39. Doring G, Flume P, Heijerman H, Elborn JS. Consensus Study G. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros 2012;11:461-479.
40. D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Deziel E, Smith EE, Nguyen H, Ernst RK, Larson Freeman TJ, Spencer DH, et al. Growth phenotypes of Pseudomonas aeruginosa lasr mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol 2007;64: 512-533.
41. Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, et al. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest 2006;116:436-446.
42. Ciofu O. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. APMIS Suppl 2003;116:1-47.
43. Doring G, Parameswaran IG, Murphy TF. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev 2011; 35:124-146.
44. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005; 55:921-927.
45. Wilder CN, Allada G, Schuster M. Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect Immun 2009;77: 5631-5639.
46. Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, Rabin HR, Surette MG. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 2013;8:e60225.
47. Ashish A, Paterson S, Mowat E, Fothergill JL, Walshaw MJ, Winstanley C. Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis. J Cyst Fibros 2013;12:790-793.
48. Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HO, Aanaes K, von Buchwald C, et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012;6:31-45.
49. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28: 321-328.